Protocol Ledger

NCT06623461 · Phase II · RECRUITING

LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

Interventional Phase II clinical trial protocol NCT06623461 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-07 Enrollment: 128 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06623461
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)128 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06623461
Protocol FieldVerified Registry Value
NCT IdentifierNCT06623461
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment128 participants (ESTIMATED)
Registered Start Date2025-04-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06623461
Hospital Research SiteLocationSite Profile
University Health NetworkToronto, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI